Latest Insider Transactions at Selecta Biosciences Inc (SELB)
This section provides a real-time view of insider transactions for Selecta Biosciences Inc (SELB). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of SELECTA BIOSCIENCES INC to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of SELECTA BIOSCIENCES INC's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 28
2022
|
Carsten Brunn President and CEO |
SELL
Open market or private sale
|
Direct |
2,692
-0.5%
|
$2,692
$1.66 P/Share
|
|
Sep 02
2022
|
Carsten Brunn President and CEO |
SELL
Open market or private sale
|
Direct |
4,768
-0.87%
|
$4,768
$1.85 P/Share
|
|
Sep 01
2022
|
Carsten Brunn President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
10,937
+1.97%
|
-
|
|
Jun 13
2022
|
Carrie Smith Cox Director |
BUY
Open market or private purchase
|
Direct |
130,000
+37.91%
|
$130,000
$1.15 P/Share
|
|
Jun 01
2022
|
Carsten Brunn President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
10,938
+2.01%
|
-
|
|
May 09
2022
|
Timothy C Barabe Director |
BUY
Open market or private purchase
|
Direct |
50,000
+16.67%
|
$0
$0.77 P/Share
|
|
Apr 11
2022
|
Timothy A Springer Director |
BUY
Open market or private purchase
|
Indirect |
6,681,600
+18.28%
|
-
|
|
Mar 02
2022
|
Carsten Brunn President and CEO |
SELL
Open market or private sale
|
Direct |
5,443
-1.03%
|
$5,443
$1.81 P/Share
|
|
Mar 01
2022
|
Carsten Brunn President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
10,937
+2.03%
|
-
|
|
Jan 14
2022
|
Timothy C Barabe Director |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+4.76%
|
$20,000
$2.1 P/Share
|
|
Jan 05
2022
|
Carsten Brunn President and CEO |
SELL
Open market or private sale
|
Direct |
13,597
-2.56%
|
$40,791
$3.09 P/Share
|
|
Jan 05
2022
|
Lloyd P. Johnston Chief Operations Officer |
SELL
Open market or private sale
|
Direct |
3,416
-1.91%
|
$10,248
$3.09 P/Share
|
|
Jan 05
2022
|
Takashi Kei Kishimoto Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
3,416
-1.26%
|
$10,248
$3.09 P/Share
|
|
Jan 05
2022
|
Peter G Traber Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
3,226
-1.27%
|
$9,678
$3.09 P/Share
|
|
Jan 03
2022
|
Carsten Brunn President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
226,300
+29.86%
|
-
|
|
Jan 03
2022
|
Lloyd P. Johnston Chief Operations Officer |
BUY
Grant, award, or other acquisition
|
Direct |
72,000
+28.72%
|
-
|
|
Jan 03
2022
|
Takashi Kei Kishimoto Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
72,000
+20.94%
|
-
|
|
Jan 03
2022
|
Kevin Tan Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
72,000
+48.32%
|
-
|
|
Jan 03
2022
|
Peter G Traber Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
90,200
+26.16%
|
-
|
|
Dec 15
2021
|
Timothy A Springer Director |
BUY
Open market or private purchase
|
Indirect |
211,190
+0.9%
|
$422,380
$2.99 P/Share
|
|
Dec 13
2021
|
Timothy A Springer Director |
BUY
Open market or private purchase
|
Indirect |
14,592
+0.06%
|
$29,184
$2.98 P/Share
|
|
Dec 10
2021
|
Carsten Brunn President and CEO |
SELL
Open market or private sale
|
Direct |
17,196
-5.33%
|
$34,392
$2.99 P/Share
|
|
Dec 10
2021
|
Lloyd P. Johnston Chief Operations Officer |
SELL
Open market or private sale
|
Direct |
4,370
-3.93%
|
$8,740
$2.99 P/Share
|
|
Dec 10
2021
|
Takashi Kei Kishimoto Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
4,370
-2.14%
|
$8,740
$2.99 P/Share
|
|
Dec 10
2021
|
Peter G Traber Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
4,083
-2.42%
|
$8,166
$2.99 P/Share
|
|
Dec 10
2021
|
Timothy A Springer Director |
BUY
Open market or private purchase
|
Indirect |
58,681
+0.25%
|
$117,362
$2.99 P/Share
|
|
Dec 09
2021
|
Timothy A Springer Director |
BUY
Open market or private purchase
|
Indirect |
3,748,000
+14.06%
|
$11,244,000
$3.06 P/Share
|
|
Dec 08
2021
|
Carsten Brunn President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
37,500
+10.42%
|
-
|
|
Dec 08
2021
|
Lloyd P. Johnston Chief Operations Officer |
BUY
Grant, award, or other acquisition
|
Direct |
13,750
+11.01%
|
-
|
|
Dec 08
2021
|
Takashi Kei Kishimoto Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
13,750
+6.31%
|
-
|
|
Dec 08
2021
|
Peter G Traber Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
13,750
+7.55%
|
-
|
|
Dec 03
2021
|
Carrie Smith Cox Director |
BUY
Open market or private purchase
|
Direct |
17,200
+17.19%
|
$34,400
$2.95 P/Share
|
|
Dec 02
2021
|
Nishan M De Silva Director |
BUY
Open market or private purchase
|
Direct |
7,000
+50.0%
|
$14,000
$2.96 P/Share
|
|
Dec 02
2021
|
Kevin Tan Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
5,000
+50.0%
|
$15,000
$3.03 P/Share
|
|
Dec 02
2021
|
Carsten Brunn President and CEO |
SELL
Open market or private sale
|
Direct |
4,746
-1.64%
|
$9,492
$2.96 P/Share
|
|
Dec 01
2021
|
Carsten Brunn President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
10,938
+3.64%
|
-
|
|
Oct 13
2021
|
Carsten Brunn President and CEO |
SELL
Open market or private sale
|
Direct |
15,313
-5.21%
|
$61,252
$4.39 P/Share
|
|
Oct 13
2021
|
Lloyd P. Johnston Chief Operations Officer |
SELL
Open market or private sale
|
Direct |
3,892
-3.84%
|
$15,568
$4.39 P/Share
|
|
Oct 13
2021
|
Takashi Kei Kishimoto Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
3,892
-2.0%
|
$15,568
$4.39 P/Share
|
|
Oct 13
2021
|
Peter G Traber Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
3,636
-2.3%
|
$14,544
$4.39 P/Share
|
|
Oct 01
2021
|
Carsten Brunn President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
37,500
+11.31%
|
-
|
|
Oct 01
2021
|
Lloyd P. Johnston Chief Operations Officer |
BUY
Grant, award, or other acquisition
|
Direct |
13,750
+11.96%
|
-
|
|
Oct 01
2021
|
Takashi Kei Kishimoto Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
13,750
+6.61%
|
-
|
|
Oct 01
2021
|
Peter G Traber Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
13,750
+7.99%
|
-
|
|
Sep 24
2021
|
Carsten Brunn President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
27,200
+9.59%
|
-
|
|
Sep 24
2021
|
Peter G Traber Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
9,100
+5.92%
|
-
|
|
Sep 02
2021
|
Carsten Brunn President and CEO |
SELL
Open market or private sale
|
Direct |
4,523
-1.93%
|
$18,092
$4.51 P/Share
|
|
Sep 01
2021
|
Carsten Brunn President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
10,937
+4.47%
|
-
|
|
Aug 18
2021
|
Timothy C Barabe Director |
BUY
Open market or private purchase
|
Direct |
9,000
+4.52%
|
$36,000
$4.0 P/Share
|
|
Jun 02
2021
|
Carsten Brunn President and CEO |
SELL
Open market or private sale
|
Direct |
4,806
-2.11%
|
$19,224
$4.38 P/Share
|